Our Business Development team invites you to contact them to explore your potential development and commercialization applications using our xMAP® technology. Click here to start the conversation now.
了解更多
Webinar Wednesday: Overcome Biomarker Multiplexing Challenges in Drug Development
Paul Rhyne from BDS Shares Recommended Multiplexing Techniques
Paul Rhyne, PhD, Chief Scientific Officer at Biologic Development Services (BDS), shares insights from a review article co-authored with 11 colleagues from pharmaceutical companies, clinical research organizations (CRO), and government agencies over two years titled: Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.
Watch more videos >
March 8
Luminex Corporation to Present at the Barclays Global Healthcare Conference
February 12
Luminex Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
February 6
Luminex Corporation To Present At LEERINK Partners 7th Annual Global Healthcare Conference
January 24
Luminex Corporation Declares First Quarter Cash Dividend
January 7
Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2017
AACR Annual Meeting
April 14-18
Chicago, IL
ECCMID
April 21-24
Barcelona, Spain
Immunology 2018
May 4-8
Austin, TX
Clinical Virology Symposium (CVS)
May 6-9
West Palm Beach, FL
APHL Annual Meeting
June 2-4
Pasadena, CA
PSI Annual Meeting
June 3-6
Beurs Van Berlage, Amsterdam
